image
Healthcare - Biotechnology - NASDAQ - US
$ 1.07
-0.926 %
$ 3.03 M
Market Cap
-0.02
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EYEN stock under the worst case scenario is HIDDEN Compared to the current market price of 1.07 USD, Eyenovia, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EYEN stock under the base case scenario is HIDDEN Compared to the current market price of 1.07 USD, Eyenovia, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EYEN stock under the best case scenario is HIDDEN Compared to the current market price of 1.07 USD, Eyenovia, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EYEN

image
$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0$5.0$5.0$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
57.3 K REVENUE
1414.02%
-48.7 M OPERATING INCOME
-91.83%
-49.8 M NET INCOME
-82.75%
-30.1 M OPERATING CASH FLOW
-26.36%
-161 K INVESTING CASH FLOW
95.93%
17.6 M FINANCING CASH FLOW
-11.31%
28.1 K REVENUE
1628.80%
-19.5 M OPERATING INCOME
-165.29%
-20 M NET INCOME
-152.98%
-6.11 M OPERATING CASH FLOW
-2.81%
-1 INVESTING CASH FLOW
99.94%
1.04 M FINANCING CASH FLOW
-90.36%
Balance Sheet Eyenovia, Inc.
image
Current Assets 2.77 M
Cash & Short-Term Investments 2.12 M
Receivables 0
Other Current Assets 646 K
Non-Current Assets 901 K
Long-Term Investments 0
PP&E 718 K
Other Non-Current Assets 182 K
57.84 %17.61 %19.59 %4.97 %Total Assets$3.7m
Current Liabilities 16 M
Accounts Payable 2.2 M
Short-Term Debt 10.5 M
Other Current Liabilities 3.32 M
Non-Current Liabilities 718 K
Long-Term Debt 718 K
Other Non-Current Liabilities 0
13.12 %62.78 %19.82 %4.28 %Total Liabilities$16.8m
EFFICIENCY
Earnings Waterfall Eyenovia, Inc.
image
Revenue 57.3 K
Cost Of Revenue 3.93 M
Gross Profit -3.87 M
Operating Expenses 44.9 M
Operating Income -48.7 M
Other Expenses 1.08 M
Net Income -49.8 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)57k(4m)(4m)(45m)(49m)(1m)(50m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-6749.50% GROSS MARGIN
-6749.50%
-85004.58% OPERATING MARGIN
-85004.58%
-86888.57% NET MARGIN
-86888.57%
380.41% ROE
380.41%
-1358.28% ROA
-1358.28%
2627.85% ROIC
2627.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Eyenovia, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -49.8 M
Depreciation & Amortization 1.13 M
Capital Expenditures -161 K
Stock-Based Compensation 1.7 M
Change in Working Capital -340 K
Others 16.4 M
Free Cash Flow -30.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Eyenovia, Inc.
image
EYEN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Eyenovia, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
42.6 K USD 1
6-9 MONTHS
1 M USD 1
9-12 MONTHS
7. News
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 globenewswire.com - 3 weeks ago
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platform globenewswire.com - 1 month ago
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule. globenewswire.com - 2 months ago
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs globenewswire.com - 2 months ago
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization globenewswire.com - 2 months ago
Eyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives globenewswire.com - 3 months ago
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th globenewswire.com - 3 months ago
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% globenewswire.com - 3 months ago
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”),  an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company's stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 4 months ago
Eyenovia Provides Update on Restructuring Efforts Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025 globenewswire.com - 5 months ago
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee. zacks.com - 5 months ago
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia. benzinga.com - 5 months ago
8. Profile Summary

Eyenovia, Inc. EYEN

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.03 M
Dividend Yield 0.00%
Description Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Contact 295 Madison Avenue, New York, NY, 10017 https://www.eyenovia.com
IPO Date Jan. 25, 2018
Employees 13
Officers Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder & Executive Director Mr. Enrico Brambilla Senior Vice President of R&D Mr. Bren Kern Chief Operating Officer & Corporate Vice President Mr. Michael M. Rowe Principal Financial Officer, Chief Executive Officer, President & Director Alexander Lobo Investor Contact Mr. Norbert Lowe Senior Vice President of Commercial Operations